The extension provides Agile Therapeutics with a longer runway to address its stockholders' equity issue, which may instill some confidence in investors and reduce the immediate threat of a delisting. This positive regulatory development could lead to a short-term uptick in the stock price as the pressure of meeting the compliance deadline is temporarily alleviated.